1 2 Accuracy and clinical effectiveness of risk prediction tools for 3 pressure injury occurrence: An umbrella review 4 5 6 Bethany Hillier^{1,2} 7 8 Katie Scandrett^{1,2} April Coombe^{1,2} 9 Tina Hernandez-Boussard³ 10 11 Ewout Steverberg⁴ Yemisi Takwoingi^{1,2} 12 Vladica Velickovic^{5,6} 13 Jacqueline Dinnes^{1,2*} 14 15 16 Affiliations 17 ¹Biostatistics, Evidence Synthesis, Test Evaluation And Prediction Modelling (BESTEAM), Institute of 18 Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK 19 ² NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation 20 Trust and University of Birmingham, Birmingham, UK 21 ³ Department of Medicine, Stanford University, Stanford, CA USA ⁴ Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The 22 23 Netherlands ⁵ Evidence Generation Department, HARTMANN GROUP, Heidenheim, Germany 24 25 ⁶ Institute of Public Health, Medical, Decision Making and Health Technology Assessment, UMIT, Hall, 26 Tirol, Austria 27 * Corresponding author: 28 29 E-mail: j.dinnes@bham.ac.uk (JD) 30 31 **Keywords** 32 Sensitivity, specificity, AUC, AUROC, prognostic model, clinical scale, pressure injury, pressure ulcer,

33 incidence, umbrella review, overview
 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 ABSTRACT

35 Background

- 36 Pressure injuries (PIs) pose a substantial healthcare burden and incur significant costs worldwide.
- 37 Several risk prediction models to allow timely implementation of preventive measures and
- 38 potentially reduce healthcare system burden are available and in use. The ability of risk prediction
- tools to correctly identify those at high risk of PI (prognostic accuracy) and to have a clinically
- 40 significant impact on patient management and outcomes (effectiveness) is not clear.
- 41 We aimed to evaluate the prognostic accuracy and clinical effectiveness of risk prediction tools for PI,
- 42 and to identify gaps in the literature.

43 Methods and Findings

- 44 The umbrella review was conducted according to Cochrane guidance. MEDLINE, Embase, CINAHL,
- 45 EPISTEMONIKOS, Google Scholar and reference lists were searched to identify relevant systematic
- 46 reviews. Risk of bias was assessed using adapted AMSTAR-2 criteria. Results were described
- 47 narratively.
- 48 We identified 16 reviews that assessed prognostic accuracy and 10 that assessed clinical
- 49 effectiveness of risk prediction tools for PI. The 16 reviews of prognostic accuracy evaluated 63 tools
- 50 (39 scales and 24 machine learning models), with the Braden, Norton, Waterlow, Cubbin-Jackson
- 51 scales (and modifications thereof) the most evaluated tools. Meta-analyses from a focused set of
- 52 included reviews showed that the scales had sensitivities and specificities ranging from 53%-97% and
- 53 46%-84%, respectively. Only 2/16 reviews performed appropriate statistical synthesis and quality
- 54 assessment. One review assessing machine learning based algorithms reported high prognostic
- accuracy estimates, but some of which were sourced from the same data within which the models
- 56 were developed, leading to potentially overoptimistic results.
- 57 Two randomised trials assessing the effect of PI risk assessment tools on incidence of PIs were
- 58 identified from the 10 systematic reviews of clinical effectiveness; both were included in a Cochrane
- review and assessed as high risk of bias. Both trials found no evidence of an effect on PI incidence.

60 Conclusions

- 61 Our findings underscore the lack of high-quality evidence for the accuracy of risk prediction tools for
- 62 PI. There is no reliable evidence to suggest that using existing risk prediction tools effectively reduces
- 63 the incidence of PIs. Further research is needed on their clinical effectiveness, but only once
- 64 promising prediction tools have been developed and appropriately validated.

65 INTRODUCTION

- 66 Pressure injuries (PI), also known as pressure ulcers or decubitus ulcers, have an estimated global
- 67 prevalence of 12.8% among hospitalised adults,¹ and place a significant burden on healthcare
- 68 systems (estimated at \$26.8 billion per year in the US alone²). PIs are most common in individuals
- 69 with reduced mobility, limited sensation, poor circulation, or compromised skin integrity, and can
- 70 affect those in community settings and long-term care as well as hospital settings. Effective
- 71 prevention of PI requires multicomponent preventive strategies such as mattresses, overlays, and
- 72 other support systems, nutritional supplementation, repositioning, dressings, creams, lotions, and
- 73 cleansers.³ It is therefore important to correctly identify those most at risk of PI to allow timely and
- targeted implementation of preventive measures, to reduce harm and consequently burden to
- 75 healthcare systems.⁴
- 76 Numerous clinical assessment scales (e.g. Braden⁵⁶, Norton⁷ and Waterlow⁸) and statistical risk
- prediction models for assessing the risk of PI are available however, many are limited by reliance on
- 78 subjective clinical judgment and do not appear to meet basic standards for the development or
- 79 reporting of risk prediction models.⁹ Nevertheless, many such tools are in routine clinical usage. For
- 80 example, in certain hospitals and long-term care settings in the US, healthcare professionals must
- 81 conduct mandatory risk assessments for PI for all patients for the purposes of risk stratification and
- 82 clinical triage.
- 83 Despite the apparent lack of sound methods for development and validation (including external
- 84 validation) of available risk prediction tools, there is a considerable body of evidence evaluating their
- 85 clinical utility, much of which has been synthesised in systematic reviews and meta-analyses.⁹ Clinical
- 86 utility includes both prognostic accuracy and clinical effectiveness. Prognostic accuracy is estimated
- 87 by applying a numeric threshold above (or below) which there is a greater risk of PI, with study
- results presented using accuracy metrics such as sensitivity, specificity or the area under the receiver
- 89 operating characteristic (ROC) curve.¹⁰ Resulting accuracy is driven not only by the nominated
- 90 threshold for defining participants as at low or high risk for PI but by other study factors including
- 91 population and setting.¹¹ Clinical effectiveness, or the ability of a tool to impact on health outcomes
- 92 such as the incidence or severity of PI, is related both to the accuracy of the tool (or its ability to
- 93 correctly identify those most likely to develop PI) and to the uptake and implementation of the tool
- 94 in practice. Demonstrating a change in health outcomes as a result of use of a risk prediction tool is
 95 vital to encourage implementation.¹²
- 96 Using an umbrella review approach, we aimed to provide a comprehensive overview of available
- 97 systematic reviews that consider the prognostic accuracy and clinical effectiveness of PI risk
- 98 prediction tools.

99 METHODS

- 100 Protocol registration and reporting of findings
- 101 We followed Cochrane guidance for conducting umbrella reviews¹³, and 'Preferred Reporting Items
- 102 for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies' (PRISMA-DTA)
- 103 reporting guidelines¹⁴ (see Appendix 1). The protocol was registered on Open Science Framework
- 104 (<u>https://osf.io/tepyk</u>).

105 Literature search

- 106 Electronic searches of MEDLINE, Embase via Ovid and CINAHL Plus EBSCO from inception to January
- 107 2023 were developed and conducted by an experienced information specialist (AC), employing well-

- 108 established systematic review and prognostic search filters,¹⁵⁻¹⁷ combined with appropriate keywords
- 109 related to PIs. Simplified supplementary searches in EPISTEMONIKOS and Google Scholar were also
- 110 undertaken (see Appendix 2 for further details). Screening of search results and full texts were
- 111 conducted independently and in duplicate by two reviewers (BH, JD, YT, KS), with disagreements
- 112 resolved by a third reviewer.
- 113 Eligibility criteria for this umbrella review
- 114 Published English-language systematic reviews of risk prediction tools developed for adult patients at
- risk of PI in any setting were included. Clinical risk assessment scales and models developed using
- 116 statistical or machine learning (ML) methods were eligible (models exclusively using pressure sensor
- data were not considered). Risk prediction tools could be applied by any healthcare professional
- using any threshold for classifying patients as high or low risk and using any PI classification system¹⁸⁻
- ²¹ as a reference standard. For prognostic accuracy, we required accuracy metrics, such as sensitivity
- and specificity, to be presented but did not require full 2x2 classification tables to be reported.
- 121 Reviews on diagnosing or staging suspected or existing PIs were excluded.
- 122 To be considered 'systematic', reviews were required to report a thorough search of at least two
- 123 electronic databases and at least one other indication of systematic methods (e.g. explicit eligibility
- 124 criteria, formal quality assessment of included studies, adequate data presentation for
- 125 reproducibility of results, or review stages (e.g. search screening) conducted independently in
- 126 duplicate).

127 Data extraction and quality assessment

- 128 Data extraction forms (Appendix 3) were informed by the CHARMS checklist (CHecklist for critical
- 129 Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) and Cochrane
- 130 Prognosis group template.^{22 23} Data extraction items included review characteristics, number of
- 131 studies and participants, study quality and results.
- 132 The methodological quality of included systematic reviews was assessed using AMSTAR-2 (A
- 133 Measurement Tool to Assess Systematic Reviews)²⁴, adapted for systematic reviews of risk prediction
- models (Appendix 4). Our adapted AMSTAR-2 contains six critical items, and limitations in any of
- these items reduces the overall validity of a review.²⁴ Quality assessment and data extraction were
- 136 conducted by one reviewer and checked by a second (BH, JD, KS), with disagreements resolved by
- 137 consensus.

138 Synthesis methods

- 139 Reviews about prognostic accuracy and clinical effectiveness of risk prediction tools were considered
- 140 separately. Review methods and results were tabulated and a narrative synthesis provided.
- 141 Prognostic accuracy results from reviews including a statistical synthesis were tabulated according to
- 142 risk prediction tool.
- 143 Considerable overlap in risk prediction tools and included primary studies was noted between
- 144 reviews. For risk prediction tools that were included in multiple meta-analyses, we focused our
- synthesis on the review(s) with the most recent search date or most comprehensive (based on
- 146 number of included studies) and most robust estimate of prognostic accuracy (judged according to
- 147 the appropriateness of the meta-analytic method used, e.g. use of recommended hierarchical
- 148 approaches for test accuracy data²⁵). The prognostic accuracy of risk prediction tools that were
- included in three or fewer reviews, was reported only if an appropriate method of statistical
- 150 synthesis¹³ was used.

- 151 For clinical effectiveness results, reviews with the most recent search date or most comprehensive
- 152 overview of available studies and that at least partially met more of the AMSTAR-2 criteria²⁴ were
- 153 prioritised for narrative synthesis.


154 RESULTS

155 Characteristics of included reviews

- 156 A total of 110 records were selected for full-text assessment from 6302 unique records. We could
- obtain the full text of 104 publications, of which 23 reviews met all eligibility criteria (Figure 1), 16
- reported accuracy data²⁴⁻³⁹ and 10 reported clinical effectiveness data^{25 29 34 40-46} (three reported both
- accuracy and effectiveness data^{25 29 34}). Table 1 and Figure 2 provide an overview of the
- 160 characteristics, methods and methodological quality of all 23 reviews (see Appendix 5 for full
- 161 details).

162

163 Figure 1. PRISMA²⁶ flowchart: identification, screening and selection process



164

165 List of full-text articles excluded, with reasons, is given in Appendix 5.

166

167 Tabl	e 1. Summary	of included systematic	review characteristics
----------	--------------	------------------------	------------------------

Review characteristic	Reviews on prognostic accuracy of risk prediction tools (N=16)	Reviews on clinical effectiveness of risk prediction tools (N=10)	All included reviews (N=23)
Median (range) year of publication	2016 (2006 – 2022)	2014 (2006 – 2021)	2016 (2006 – 2022)
Eligibility criteria			
Participants			
Adults only	9 (56) ^A	5 (50)	13 (57) ^A
Any age	2 (13)	1 (10)	3 (13)
No age restriction reported	5 (31)	4 (40)	7 (30)
Presence of PI at baseline			
Excluded (no PI at baseline)	5 (31)	2 (20)	6 (26)
NS	11 (69)	7 (70)	17 (74)
Setting			
Any healthcare setting	6 (38)	5 (50)	10 (43)
Hospital	2 (13)	2 (20)	4 (22)
Long-term care	2 (13)	0 (0)	2 (9)
Acute care (incl. surgical and ICU)	5 (31)	2 (20)	6 (26)
Long-term, acute or community settings	1 (6)	1 (10)	1 (4)
Risk assessment tools			
Any prediction tool or scale	5 (31)	6 (60)	9 (39)
Specified clinical scale(s)	8 (50)	2 (20)	10 (43)
ML-based prediction models	1 (6)	0 (0)	1 (4)
PI prevention strategies	0 (0)	1 (10)	1 (4)
NS	2 (13)	1 (10)	2 (9)
PI classification system			
Any	1 (6)	0 (0)	1 (4)
Accepted standard classifications	1 (6)	1 (10)	2 (9)
Several specified classification systems (NPUAP, EPUAP, AHCPR or TDCPS)	3 (19)	1 (10)	3 (13)
PI stage predefined ²⁷ /defined by study authors	1 (6)	0 (0)	1 (4)
NS	10 (63)	8 (80)	16 (70)
Source of data			
Prospective only	4 (25)	2 (20)	4.5 (20) ^B
Prospective or retrospective	1 (6)	2 (20)	2.5 (7) ^в
NS	11 (69)	6 (60)	16 (60)
Study design restrictions			
Yes	7 (44)	6 (60)	12 (52)
No	2 (13)	2 (20)	3 (13)
NS	7 (44)	2 (20)	8 (39)
Phase of development/evaluation of tools			
External evaluations only	1 (6)	N/A	N/A
Validation studies (internal or external NS)	1 (6)	N/A	N/A
NS	14 (88)	N/A	N/A
Review methods			
Median (range) no. sources ^c searched	6 (2 – 14)	5 (3 – 14)	6 (2 – 14)
Publication restrictions:		. ,	
End date (year)			
2000-2009	1 (6)	3 (30)	3 (13)
2010-2019	12 (75)	6 (60)	16 (70)
2020-2023	3 (19)	1 (10)	4 (17)
Language			

wiedidii (laiige) iio. toois	4 (1 - 28)	3(2-9)	
Median (range) no. participants Median (range) no. tools	11,729 (609 – 221,541) 4 (1 – 28)	1,910 (528 – 2,273) 3 (2 – 9)	6,106 (528 – 221,541) 3 (1 – 28)
Median (range) no. studies	19 (2 – 70)	4 (1 – 20)	13 (1 – 70)
Volume of evidence			
Unclear/NS	4 (31) ^F	N/A	N/A
Hierarchical model (for DTA studies)	2 (15)	N/A	N/A
Univariate RE model	5 (38) ^F	N/A	N/A
Univariate RE/FE model (depending on heterogeneity assessment)	2 (15) ^F	N/A	N/A
(% of reviews incl. meta-analysis)			
Meta-analysis included Method of meta-analysis	13 (81)	0 (0)	13 (57)
None	3 (19)	2 (20)	4 (17)
Other	1 (6)	4 (40)	5 (22)
Cochrane RoB tool	0 (0)	1 (10)	1 (4)
CASP	2 (13)	1 (10)	2 (9)
JBI tools	1 (6)	2 (20)	3 (13)
QUADAS-2	7 (44)	N/A	7 (30)
QUADAS	2 (13)	N/A	2 (9)
PROBAST	0 (0) ^E	N/A	0 (0) ^E
Quality assessment tool D			
NS	5 (31)	0 (0)	5 (22)
No restrictions	3 (19)	1 (10)	4 (17)
>2 languages	2 (13)	2 (20)	3 (13)
2 languages	0 (0)	2 (20)	2 (9)
English only	6 (38)	6 (60)	9 (39)

168 Figures are number (%) of reviews, unless otherwise specified. ^A one review²⁸ restricted to aged >60 years; ^B one review²⁹ 169 states either prospective or retrospective data eligible for Research Question 1, but prospective only for Research Question 170 2, hence 0.5 added to each category; ^c including databases, bibliographies or registries; ^D reviews may fall into multiple 171 categories, therefore total number within domain not necessarily equal to N (100%); ^E one review³⁰ reported use of 172 PROBAST in methods, but did not present any PROBAST results; ^F one review conducts univariate meta-analysis for single 173 estimate, e.g. AUC³¹, RR³² or OR³³; AHCPR – Agency for Health Care Policy and Research; AUC – area under the curve; CASP 174 - Critical Appraisal Skills Programme; DTA - diagnostic test accuracy; EPUAP - European Pressure Ulcer Advisory Panel; FE -175 fixed effects; ICU - intensive care unit; JBI - Joanna Briggs Institute; ML - machine learning; NPUAP - National Pressure 176 Ulcer Advisory Panel; NS - not stated; OR - odds ratio; PI - pressure injury; PROBAST - Prediction model Risk of Bias 177 Assessment; QUADAS (2) - Quality Assessment of Diagnostic Accuracy Studies (Version 2); RE - random effects; RR - risk 178 ratio; TDCPS – Torrance Developmental Classification of Pressure Sore.

179

		Reviews reporting prognostic accuracy (n=16)			Reviews reporting clinical effectiveness (n=10)									
ITEM 1 Research question		4			12				3			7		
ITEM 2 Protocol		4			12				3		1		6	
ITEM 3 Inclusions	2			14	Ļ			1				9		
ITEM 4 Search strategy	1			12			3		2			7		1
ITEM 5 Study selection			10			6				6	I.		4	
ITEM 6 Data extraction			8			8				5			5	
ITEM 7 Exclusions	1			15					2			8		
ITEM 8 Study descriptions		4	3		9						8		1	1
ITEM 9 RoB/QA		4	3		9				2		4		4	
ITEM 10 Funding of incl. studies	1			15					2			8		
ITEM 11 Statistical synthesis		4		10)		2				1	.0		
ITEM 12 RoB – impact on synthesis		4		10)		2				1	.0		
ITEM 13 RoB – impact on results			8			8					7		3	
ITEM 14 Heterogeneity			9			7				5			5	
ITEM 15 Conflicts of interest			11			5					7		3	
	0%	20	9% 4	0% 6	50%	80%	100%	0%	2	20%	40%	60%	80%	100

Figure 2. Summary of AMSTAR-2 assessment results.

181 Item 1 – Adequate research question/ inclusion criteria?; Item 2 – Protocol and justifications for deviations?; Item 3 – Reasons for study design inclusions?; Item 4 – Comprehensive search

strategy?; Item 5 – Study selection in duplicate?; Item 6 – Data extraction in duplicate?; Item 7 – Excluded studies list (with justifications)?; Item 8 – Included studies description adequate?;
 Item 9 – Assessment of RoB/quality satisfactory?; Item 10 – Studies' sources of funding reported?; Item 11 – Appropriate statistical synthesis method?; Item 12 – Assessment of RoB

184 on synthesised results?; Item 13 – Assessment of impact of RoB on review results?; Item 14 – Discussion/investigation of heterogeneity?; Item 15 – Conflicts of interest reported?; N/A – Not

185 Applicable; RoB – Risk of Bias; QA – quality assessment. Further details on AMSTAR items are given in Appendix 4, and results per review are given in Appendix 5.

186 Reviews were published between 2006 and 2022. Approximately half (12/23, 52%) restricted

- inclusion to adult populations (Table 1), three included any age group, and nine (39%) did not report
- any age restrictions. Six reviews (6/23, 26%) specified only populations without PIs at baseline for
- inclusion. Acute care was the most common setting across both review questions, 5/16 (31%) and
- 4/10 (40%) for accuracy and effectiveness reviews, respectively. Quality assessment tools varied, with
 QUADAS-2 (n=7) or QUADAS (n=2) being most common for reviews of accuracy (9/16, 56%). One
- accuracy review³⁰ reported use of both QUADAS-2 and PROBAST tools in their methods, but only
- 192 accuracy review reported use of both QOADAS-2 and PROBAST tools in their methods
- 193 reported QUADAS-2 results.
- 194 Reviews of accuracy predominantly focused on studies using any (5/16, 31%) or pre-specified (8/16,
- 195 50%) risk assessment tools or scales, one included only ML-based prediction models.³⁰ A total of 63
 196 risk prediction tools were reported across the reviews, including 24 ML models. The number of
- included risk prediction tools in a single review ranged from one³⁴⁻³⁹ to 28³². Only two reviews
- 198 reported eligibility criteria related to the development or validation of the risk prediction tools. One³³
- (6%) excluded evaluation studies that used the same data that was used to develop the tool and the
- 200 other²⁹ included only "validated risk assessment instruments", however this was not further defined
- and the review included studies reporting the original development of risk prediction tools.
- 202 The majority (13/16, 81%) of accuracy reviews conducted a statistical synthesis of data, however only
- 203 two utilised currently recommended hierarchical approaches for the meta-analysis of test accuracy
- 204 data,^{36 40} seven conducted univariate meta-analysis of individual accuracy measures (e.g. sensitivity
- and specificity separately, or AUC³¹, RR³² or odds ratio³³) and four did not clearly report the type of
 analysis approach used.
- 207 Of the 10 systematic reviews evaluating the clinical effectiveness of risk prediction tools, two only
- 208 considered the reliability of risk assessment scales^{41,42} and eight considered effects on patient
- 209 outcomes (one of which also considered tool reliability⁴³). More than half of reviews (6, 60%)
- 210 compared use of PI risk assessment scales to clinical judgement alone or 'standard care'. The number
- of included studies ranged from one⁴⁴ to 20⁴⁵ and the sample sizes of primary studies ranged from
- one (one subject and 110 raters, in an inter-rater reliability study⁴⁶) to 3,027 patients. Reported
- outcomes included the incidence of PIs (7/10), preventative interventions prescribed (5/10) and
- interrater reliability (3/10) (reported in Appendix 5). One (Cochrane) review used the Cochrane RoB
- tool for quality assessment of included studies and three used JBI (n=2) or CASP (n=1) tools. Due to
- heterogeneity in study design, risk prediction tools and outcomes evaluated, none of the included
- 217 reviews provided any form of statistical synthesis of study results.
- 218 Methodological quality of included reviews
- 219 The quality of included reviews was generally poor (Figure 2; Appendix 5). The AMSTAR-2 items that
- were most consistently met (yes or partial yes) were: comprehensiveness of the search (19/23, 83%),
- study selection independently in duplicate (15/23, 65%), and conflicts of interest reported (17/23,
- 222 74%).
- 223 Of the 16 accuracy reviews, four (25%)^{30 35 36 40} used an appropriate method of quality assessment of
- included studies (i.e. QUADAS or QUADAS-2 dependent on publication year) and presented
- judgements per study. Of the 10 effectiveness reviews, two (20%)^{29 47} used an appropriate method of
- 226 quality assessment (the Cochrane tool for assessing risk of bias⁴⁸ and a criteria consistent with AHRQ
- 227 Methods Guide for Effectiveness and Comparative Effectiveness Reviews⁴⁹, respectively) and
- 228 provided judgements per study. Four reviews either reported quality assessment results per study
- 229 (n=3^{41 45 50}) or were considered to use an appropriate quality assessment tool (n=1³³) (AMSTAR-2
- criterion partially met).

- 231 Of the accuracy reviews that included a statistical synthesis, 31% (4/13)^{31 32 36 40} used an appropriate
- 232 method of meta-analysis and investigated sources of heterogeneity. Two reviews^{36 40} used
- recommended hierarchical approaches to meta-analysis of test accuracy data (the bivariate model³⁶
- and hierarchical summary ROC (HSROC) model⁴⁰) and one³¹ calculated summary AUC using random
- 235 effects meta-analysis.³²
- 236 Compared to the reviews of accuracy, reviews of effectiveness more commonly provided adequate
- descriptions of primary studies (8/10, 80% vs 4/16, 25%) (Figure 2). No other major differences
- across review questions were noted.

239 Results from reviews evaluating the prognostic accuracy of risk prediction models

Five of 16 accuracy reviews were prioritised for narrative synthesis (Tables 2-3) and are reported
below according to risk prediction tool. Four of the five reviews did not include development study

- estimates within their meta-analyses, but this information could not be ascertained for the review³⁰
- 243 of ML-based models. None of these reviews assessed the quality of development methods for the
- 244 prediction tools considered in their statistical syntheses.

245 Braden, and modified Braden scales

- 246 The most recent and largest review³⁶ of the Braden scale (60 studies, including 49,326 patients),
- which used hierarchical bivariate meta-analysis, reported an overall summary sensitivity of 0.78 (95%
- 248 CI 0.74, 0.82; 15,241 patients) and specificity of 0.72 (95% CI 0.66, 0.78; 34,085 patients) across all
- reported thresholds (range ≤10 to ≤20). Summary sensitivities and specificities ranged from 0.79
- 250 (95% CI 0.76, 0.82) and 0.66 (95% CI 0.55, 0.75) at the lowest cut-offs for identification of high-risk
- 251 patients (≤15 in 15 studies) to 0.82 (95% Cl 0.73, 0.89) and 0.70 (95% Cl 0.62, 0.77) using a cut-off of
- 18 (15 studies), respectively. Heterogeneity investigations suggested higher accuracy for predicting
 pressure injury risk in patients with a mean age of 60 years or less, in hospitalised patients
- 254 (compared to long-term care facility residents) and in Caucasian populations (compared to Asian
- populations).³⁶ The review noted a high risk of bias for the 'index test' section of the QUADAS-2
- assessment in approximately a third of included studies, but failed to provide details or reasons for
- 257 this assessment.
- 258 Two modified versions of the Braden scale^{51 52} were included by Park and colleagues.⁵³ Summary
- 259 sensitivities were 0.97 (95% Cl 0.92, 0.99; 125 patients from four studies)⁵¹ and 0.89 (95% Cl 0.71,
- 260 0.98; 27 patients from two studies)⁵², and summary specificities were 0.70 (95% Cl 0.66, 0.73; 563
- 261 patients)⁵¹ and 0.71 (95% CI 0.67, 0.75; 599 patients).⁵² The review was rated critically low on the
- AMSTAR-2 assessment, with only 3/15 (20%) criteria fulfilled. Despite reporting the use of QUADAS-2
- 263 for their risk of bias assessment, QUADAS-2 results were not reported, except that none of the
- 264 included studies were estimated to be at high risk.

265 Cubbin & Jackson scale

- 266 Zhang and colleagues⁴⁰ included six studies evaluating the original Cubbin & Jackson scale⁵⁴ (800
- 267 patients). Summary sensitivity and specificity were both reported as 0.84 (95% CIs 0.59, 0.95 and
- 268 0.66, 0.93, respectively)⁴⁰ suggesting that this represents the point on the HSROC curve where
- 269 sensitivity equals specificity, particularly as reported thresholds ranged from 24 to 34. The review
- authors concluded that although the accuracy of the Cubbin & Jackson scale was higher than the
- 271 EVARUCI scale and the Braden scale, low quality of evidence and significant heterogeneity limit the
- 272 strength of conclusions that can be drawn.

273 Table 2. Findings related to prognostic accu	racy, by model: Characteristics and quality	of studies included within reviews
--	---	------------------------------------

Review author (publication year)	Tool(s) evaluated n studies; N participants	Brief description of included studies	Brief description of included study quality	Method of meta-analysis
Huang ³⁶ (2021)	Braden ⁵⁶ n = 60; N = 49,326	Setting: hospital (n=45; includes 22 in ICU or other acute units), LTCF (n=15) Sample size: 25 to 10,098 Mean age: range 31.7±10.9 to 84.6±7.9 Design: 47 prospective, 13 retrospective Braden cut-off (out of 23): range ≤10 to ≤20 Development study not included.	QUADAS-2: Patient selection: low RoB in 11/60 (18%), unclear RoB (>50%); low concern about applicability in 44/60 (73%), high concern for applicability in 16; Index test: low RoB in 39/60 (65%), high RoB (approx. 33%); low concern about applicability in 51/60 (85%); Reference standard: low RoB in 58/60 (97%), unclear RoB in 2 (3%); low concern about applicability in 51/60 (85%), unclear concern in 9 (15%); Flow and timing: low RoB in 50/60 (83%; unclear RoB in 10 (17%).	Bivariate meta-analysis; SROC constructed; and subgroup/stratified analyses to explore heterogeneity
Zhang ⁴⁰ (2021)	4 tools evaluated in meta- analyses	Studies not described according to prediction tool. All prospective	Studies not described according to prediction tool QUADAS-2: Overall judgement was "not so satisfactory".	HSROC model for >3 studies, or univariate fixed- or random- effects models if ≤3 studies; meta-regression heterogeneity investigation
	Braden ⁵⁶	Cut-offs used range from 10.5 to 20.		
	n = 18; N = 11,167	Development study not included.		
	Cubbin & Jackson ⁵⁴	Cut-offs used range from 24 to 34.		
	n = 6; N = 800	Development study not included.		
	EVARUCI ⁵⁵ n = 3; N = 3,063	Cut-offs: >11, >11.5, NS Development study not included.		'Inconsistency' (I ² statistic) of studies was found to be 0%, therefore univariate fixed-effect models used
	Waterlow ⁸	Cut-offs: 12, 16, <25, 20.5		
	n = 4; N = 1,000	Development study not included.		
Park ²⁸ (2016b)	3 tools evaluated	Studies not described according to prediction tool		DTA meta-analysis (random
		Cut-offs selected "by following the one which the study researcher(s) indicated to be the most effective".		effects) using MetaDiSc; no further details

	Braden ⁵⁶ n = 25; N = 10,547	cut-off: 13 (n=2); 16 (n=8); 17 (n=2); 18 (n=9); 19 (n=3); 20 (n=1) Development study not included.		
	Norton ⁷ n = 5; N = 2,408	cut-offs: 14 (n=2); 16 (n=3) Development study not included.		
	Waterlow ⁸ n = 5; N = 1,406	15 (n=1); 16 (n=2); 17 (n=1); NS (n=1) Development study not included.		
Park ⁵³ (2016a)	5 tools evaluated	Described below according to prediction tool	QUADAS-2: Studies not described according to prediction tool "None had 'high risk'"	DTA meta-analysis (random- effects) using MetaDiSc; Cochrane Handbook (2010) ⁵⁶ and Walter 2002 ⁵⁷ cited
	Braden – modified by Song & Choi ⁵¹ n = 4; N = 688	Prospective (4/4), recruiting patients with no PI at baseline (hospital ward (n=2) or ICU (n=3); mean age in the 50s (n=2), 60s (n=2). Classification used: AHCPR (n=3), Bergstrom (n=1). Braden scale cut-off used: <21 (n=1), <23 (n=1), <24 (n=2) Development study not included.		
	Braden – modified by Pang & Wong ⁵² n = 2; N = 626	Prospective (2/2), recruiting patients with no PI at baseline (OS ward (n=1) or NS (n=1); mean age 79.4 and 54.1. Classification used: NPUAP (n=2) Braden scale cut-off used: <19 (n=1), <14 (n=1) Development study not included.		
	Cubbin & Jackson ⁵⁴ n = 4; N = 662	Prospective (4/4); ICU patients for all studies (1 in surgical ICU), with no PI at baseline (n=3); mean age in the 50s (n=2), 60s (n=2). Classification used: AHCPR (n=2), NPUAP (n=1), Lowthian (n=1). C&J scale cut-off used: <24 (n=2), <26 (n=1), <28 (n=1) Development study not included.		
	Norton ⁷ n = 7; N = 2,899	Prospective (6/7); inpatients with no PI at baseline (1 LTC, 2 'hospital', 1 ICU, 1 ICU & wards); mean age in the 50s (n=1), 60s (n=3), or 80s (n=1), or NS (n=2). Classification used: AHCPR (n=3), NPUAP (n=2), EPUAP (n=1), TDCPS (n=1). Norton scale cut-off used: <14 (n=2, but reported as 3 in paper), <15 (n=2), <16 (n=3) Development study not included.		
	Waterlow ⁸	Prospective (6/6); all male* inpatients aged over 60 on		
	n = 6; N = 1,268	average with no PI at baseline (3 included ICU patients).		

		Classification used: AHCPR (n=2), NPUAP (n=2), EPUAP (n=1), TDCPS (n=1). Waterlow scale cut-off used: <9 (n=1), <15 (n=1), <16 (n=2), <17 (n=1), NS (n=1) Development study not included.			
Qu ³⁰ (2022)	Models by ML algorithm type	Characteristics only reported overall, not by algorithm type.	QUADAS-2 details reported overall, not by algorithm type.	RevMan (Moses & Littenberg method ^{58 59}) for analysis of	
	Decision Tree n = 14; N = 118,292	Conducted in: hospital patients (n= 13); surgical patients (n=3), ICU (n=5), CVD patients (n=2), cancer patients	2/14 high RoB; 10/14 low RoB; 2/14 unclear RoB	quantitative data (SROC plot presented) and Bayesian DTA-	
	Logistic Regression n = 14; N = 195,927	(n=1), LTC (n=1) Unclear whether development, internal validation or	4/14 high RoB; 9/14 low RoB; 1/14 unclear RoB	NMA	
	Neural Network n = 9; N = 97,815	external validation studies included.	1/9 high RoB; 7/9 low RoB; 1/9 unclear RoB		
	Random Forest n = 7; N = 161,334		1/7 high RoB; 6/7 low RoB.		
	Support Vector Machine n = 9; N = 152,068		1/9 high RoB; 8/9 low RoB.		

* as reported in review's text. However, the table reports a mixture of female and male participants for all studies, with a mean female proportion of 50.73%.

275 AHCPR – Agency for Health Care Policy and Research; CI – confidence interval; CVD – cardiovascular disease; DTA – diagnostic test accuracy; EPUAP – European Pressure Ulcer Advisory Panel;

276 (H)SROC – (hierarchical) summary receiver operating characteristic curve; ICU – intensive care unit; LTC(F) – long-term care (facility); ML – machine learning; N – number of participants; n –

277 number of studies; NMA – network meta-analysis; NS – not stated; NPUAP – National Pressure Ulcer Advisory Panel; PI – pressure injury; PPPU – Panel for the Prediction and Prevention of

278 Pressure Ulcers; QUADAS – Quality Assessment of Diagnostic Accuracy Studies; RCT – randomised controlled trial; RoB – risk of bias; TDCPS – Torrance Developmental Classification of Pressure

279 Sore.

Review author (publication year)	n studies; N part- icipants	Sensitivity (95% CI) (N = no. participants with PI)	Specificity (95% CI) (N = no. participants without PI)	Likelihood ratios (95% CI)	DOR (95% CI)	AUROC (95% CI)
TOOL: Braden ⁵⁶	(1987)					
Huang ³⁶ (2021)	n = 60; N = 49,326	0.78 (0.74, 0.82) ^A N=15,241	0.72 (0.66, 0.78) ^A N=34,085	PLR 2.80 (2.30, 3.50) ^A NLR 0.30 (0.26, 0.35) ^A	9.00 (7.00, 13.00) ^A	0.82 (0.79, 0.85) ^A
					By cut-off:	By cut-off:
		By cut-off:	By cut-off:		<i>≤</i> 15: 7.00 (4.00, 12.00)	≤15: 0.80 (0.76, 0.83)
		<i>≤15</i> (n=15): 0.79 (0.76, 0.82)	<i>≤15</i> : 0.66 (0.55, 0.75)		<i>16</i> : 17.00 (8.00, 36.00)	16: 0.84 (0.80, 0.87)
		<i>16</i> (n=19): 0.75 (0.67, 0.82)	<i>16</i> : 0.85 (0.70, 0.93)		17: 14.00 (2.00, 103.00)	17: 0.73 (0.69, 0.77)
		17 (n=4): 0.69 (0.61, 0.76)	17:0.86 (0.50, 0.97)		18: 11.00 (6.00, 20.00)	18: 0.83 (0.79, 0.86)
		<i>18</i> (n=15): 0.82 (0.73, 0.89)	18: 0.70 (0.62, 0.77)		<i>≥19</i> : 4.00 (2.00, 7.00)	<i>≥19</i> : 0.67 (0.63, 0.71)
		≥19 (n=7): 0.78 (0.65, 0.87)	<i>≥19</i> : 0.54 (0.44, 0.63)			
Zhang ⁴⁰ (2021)	n = 18; N = 11,167	0.78 (0.68 <i>,</i> 0.85) ^B	0.61 (0.40, 0.79) ^B	PLR 2.00 (1.24, 3.24) NLR 0.36 (0.25, 0.52)	5.52 (2.61, 11.67)	0.78
Park ²⁸ (2016b)	n = 25;	0.72 (0.69, 0.74) ^A	0.63 (0.62, 0.64) ^A	PLR 2.31 (1.98, 2.69) ^A	6.50 (4.64, 9.11) ^A	0.79 ^A
	N = 10,547			NLR 0.43 (0.36, 0.51) A		(SE = 0.02)
TOOL: Modified	Braden scales	s: Braden – modified by Song &	Choi ⁵¹ (1991)			
Park ⁵³ (2016a)	n = 4;	0.97 (0.92, 0.99) ^A	0.70 (0.66, 0.73) ^A	PLR 3.47 (1.33, 9.06) A	56.56 (21.88, 146.21) ^A	0.95 ^A
	N = 688	N=125	N=563	NLR 0.08 (0.04, 0.19) ^A		(SE 0.02)
TOOL: Braden –	modified by F	Pang & Wong ⁵² (1998)				
Park ⁵³ (2016a)	n = 2;	0.89 (0.71, 0.98) ^A	0.71 (0.67, 0.75) ^A	PLR 2.87 (1.88, 4.38) A	16.06 (4.75, 54.35) ^A	Not calculated
	N = 626	N=27	N=599	NLR 0.17 (0.06, 0.49) ^A		
TOOL: Cubbin &	Jackson ⁵⁴ (19	91)				
Zhang ⁴⁰ (2021)	n = 6;	0.84 (0.59, 0.95) ^B	0.84 (0.66, 0.93) ^B	PLR 5.12 (2.70, 9.70)	26.45 (13.51, 51.78)	0.90
	N = 800			NLR 0.19 (0.08, 0.49)		
Park ⁵³ (2016a)	n = 4;	0.67 (0.60, 0.74) ^A	0.75 (0.71, 0.79) ^A	PLR 2.80 (1.66, 4.72) A	9.46 (2.41, 37.22) ^A	0.82 ^A
	N = 662	N=194	N=468	NLR 0.34 (0.15, 0.76) ^A		(SE 0.06)
TOOL: EVARUCI ⁵	⁵⁵ (2001)					
Zhang ⁴⁰ (2021)	n = 3;	0.84 (0.79, 0.89) ^A	0.68 (0.66, 0.70) ^A	PLR 2.32 (2.14, 2.51) ^A	9.79 (6.81, 14.07) ^A	0.82 ^A
	N = 3,063			NLR 0.25 (0.19, 0.35) ^A		
TOOL: Norton ⁷ (1962)					
Park ⁵³ (2016a)	n = 7;	0.75 (0.70, 0.79) ^A	0.57 (0.55, 0.59) ^A	PLR 1.77 (1.26, 2.50) ^A	7.57 (2.53, 22.64) ^A	0.82 ^A
	N = 2,899	N=383	N=2,516	NLR 0.49 (0.32-0.76) A		(SE 0.05)
Park ²⁸ (2016b)	n = 5; N = 2,408	0.76 (0.71, 0.80) ^A	0.55 (0.53, 0.57) ^A	PLR 1.58 (1.07, 2.34) ^A NLR 0.47 (0.29, 0.76) ^A	6.41 (1.72, 23.88) ^A	0.84 ^A (SE 0.07)
						(02 0.07)

280 Table 3. Summary estimates of accuracy parameters (main results from statistical syntheses), by prediction tool

Review author (publication year)	n studies; N part- icipants	Sensitivity (95% CI) (N = no. participants with PI)	Specificity (95% CI) (N = no. participants without PI)	Likelihood ratios (95% CI)	DOR (95% CI)	AUROC (95% CI)
TOOL: Waterlow	/ ⁸ (1985)					
Zhang ⁴⁰ (2021)	n = 4; N = 1,000	0.63 (0.48, 0.76) ^B	0.46 (0.22, 0.71) ^B	PLR 1.16 (0.66, 2.01) NLR 0.82 (0.40, 1.67)	1.42 (0.40, 5.07)	0.56
Park ⁵³ (2016a)	n = 6; N = 1,268	0.55 (0.49, 0.62) ^A N=246	0.82 (0.80, 0.85) ^A N=1,222	PLR 2.89 (1.74, 4.79) ^A NLR 0.46 (0.31, 0.70) ^A	9.22 (6.43, 13.23) ^A	0.82 ^A (SE 0.03)
Park ²⁸ (2016b)	n = 5; N = 1,406	0.53 (0.47, 0.60) ^A	0.84 (0.81, 0.86) ^A	PLR 3.09 (1.63, 5.83) ^A NLR 0.49 (0.34, 0.72) ^A	9.06 (6.30, 13.04) ^A	0.81 ^A (SE 0.03)
ML models: ^C						
Qu ³⁰ (2022) DT models	n = 14; N = 118,292	0.66 (0.42, 0.84) N=7,557	0.90 (0.78, 0.96) N=110,735	PLR 6.9 (3.2, 14.7) NLR 0.37 (0.20, 0.69)	18 (7, 49)	0.88 (0.85, 0.91)
Qu ³⁰ (2022) LR models	n = 14; N = 195,927	0.71 (0.60, 0.80) N=9046	0.83 (0.75, 0.89) N=186,881	PLR 4.3 (3.1, 5.9) NLR 0.35 (0.26, 0.46)	12 (9, 17)	0.84 (0.81, 0.87)
Qu ³⁰ (2022) NN models	n = 9; N = 97,815	0.73 (0.55, 0.86) N=9488	0.78 (0.65, 0.87) N=88,327	PLR 3.3 (2.1, 5.0) NLR 0.35 (0.21, 0.59)	9 (5, 19)	0.82 (0.79, 0.85)
Qu ³⁰ (2022) RF models	n = 7; N = 161,334	0.72 (0.26, 0.95) N=5486	0.96 (0.80, 0.99) N=155,848	PLR 16.3 (2.4, 108.9) NLR 0.29 (0.07, 1.29)	56 (3, 1258)	0.95 (0.93, 0.97)
Qu ³⁰ (2022) SVM models	n = 9; N = 152,068	0.81 (0.69, 0.90) N=6562	0.81 (0.59, 0.93) N=145,506	PLR 4.3 (1.8, 9.9) NLR 0.23 (0.13, 0.39)	19 (6, 54)	0.88 (0.85, 0.90)

281 ^A summary statistic pooled across multiple thresholds; ^B estimate derived from HSROC, but method for choosing summary point unclear; ^C it is not reported, at review level, whether the

results presented below are pooled across development, internal validation or external validation/evaluation studies.

283 AUROC – area under the receiver operating characteristic curve; CI – confidence interval; DT – decision tree; DOR – diagnostic odds ratio; HSROC – hierarchical summary receiver operating

284 characteristic curve; LR – logistic regression; ML – machine learning; NLR – negative likelihood ratio; NN – neural network; NS – not stated; PLR – positive likelihood ratio; RF – random forest;

285 SE – standard error; SVM – support vector machine.

286 Norton scale

Park and colleagues⁵³ pooled data from seven studies (2,899 participants) evaluating the Norton
 scale, across thresholds ranging from <14 to <16. They reported summary sensitivity of 0.75 (95% CI

- 0.70, 0.79) and specificity 0.57 (95% Cl 0.55, 0.59). A further four reviews presented statistically
- 290 synthesised results for the Norton scale (Appendix 5), including one review by Chou and colleagues²⁹
- which included nine studies (5,444 participants) but only reported median values for accuracy
- 292 parameters.

293 Waterlow scale

Although Zhang and colleagues⁴⁰ included the fewest participants (4 studies; 1,000 participants) of all

- six reviews that conducted a statistical synthesis of the accuracy of the Waterlow scale⁸, they
- 296 provided the most recent review. It was rated highest on AMSTAR-2 criteria and appropriately used 297 the HSROC model for meta-analysis across thresholds ranging from 12 to 25. Summary sensitivity
- 298 was 0.63 (95% CI 0.48, 0.76) and summary specificity 0.46 (95% CI 0.22, 0.71) (Table 3). A second
- 299 review⁵³ reported summary sensitivity of 0.55 (95% Cl 0.49, 0.62) and specificity 0.82 (95% Cl 0.80,
- 300 0.85) (6 studies; 1268 participants).

301 Machine learning algorithms

- 302 Qu and colleagues³⁰ conducted separate meta-analyses of 25 studies according to ML algorithm type
- 303 (Table 2). The review rated critically low on AMSTAR-2 items, with only 6/15 (40%) criteria fulfilled,
- and reported using Bayesian DTA meta-analysis. The review did not restrict inclusion to external
- evaluations of the models, and the authors did not report which estimates were sourced from
- development data or external data. The summary AUC for the five algorithms ranged from 0.82 (95%
 CI 0.79, 0.85; 9 studies with 97,815 participants) for neural network-based models to 0.95 (95% CI
- 308 0.93, 0.97; 7 studies with 161,334 participants) for random forest models (Table 3). The latter
- approach also had the highest summary specificity 0.96 (95% CI 0.80, 0.99), with sensitivity 0.72
- 310 (95% CI 0.26, 0.95). The highest summary sensitivity was observed for support vector machine
- 311 models (0.81, 95% CI 0.69, 0.90) with summary specificity 0.81 (95% CI 0.59, 0.93) (9 studies,
- 312 152,068 participants). The remaining algorithms had summary sensitivities ranging from 0.66
- 313 (decision tree models) to 0.73 (neural network models) (Table 3). Two additional ML algorithms
- evaluated in the included studies (Bayesian networks and LOS (abbreviation not explained)) had too
- few studies to allow meta-analysis (Appendix 5).

316 Other scales

- 317 In addition to the risk prediction tools reported above, Zhang and colleagues⁴⁰ reported on the
- 318 EVARUCI scale⁵⁵, presenting summary sensitivity and specificity of 0.84 (95% CI 0.79, 0.89) and 0.68
- 319 (95% CI 0.66, 0.70), respectively (3 studies; 3,063 participants). These results were pooled across
- 320 thresholds, 11 and 11.5 (one not reported).
- 321 Beyond the results covered by our five prioritised reviews, three further modifications of the Braden
- 322 scale were evaluated in statistical syntheses: Braden modified by Kwong⁶⁰, the 4-factor model⁶¹ and
- ³²³ 'extended Braden'⁶¹, revealing variable performance with high uncertainty.^{32 29 42} Another two
- 324 modified versions of the Norton scale (by Ek⁶², and by Bienstein⁶³) were also included in one review's
- meta-analyses³², but only risk ratios were reported. Three additional scales (revised "Jackson &
- 326 Cubbin^{"64}, EMINA⁶⁵ and PSPS⁶⁶) were evaluated in one statistical synthesis each.³² ²⁹ Full details can
- be found in Appendix 5 Table S4.
- 328 Appendix 5 Table S5 reports data for another 17 risk prediction tools, each associated with a single
- 329 primary study (therefore not covered in detail in the text above), and another two tools,
- 330 Sunderland⁶⁷ and RAPS⁶⁸, which are assessed in two primary studies each.

331 Results from reviews evaluating the clinical effectiveness of risk prediction models

- Table 4 provides an overview of results from four^{29 45 47 50 69} of the 10 reviews reporting clinical
- 333 effectiveness, including one Cochrane review⁴⁷ which identified two randomised controlled trials
- 334 (RCTs) of risk prediction tools and assessed risk of bias using the Cochrane RoB tool⁴⁸. The remaining
- reviews used broader eligibility criteria for study inclusion and a range of different quality
- assessment tools, with some reviews reaching varying conclusions about the methodological quality
- of the same studies. Given the overlap in study inclusion between reviews, a summary of the
- included comparative studies is provided below.
- 339 One individually randomised trial (Webster and colleagues⁷⁰) and one cluster randomised trial (Saleh
- 340 and colleagues⁷¹) were considered to be at high risk of bias by the Cochrane review authors. The
- individually randomised trial⁷⁰ was included in three additional reviews^{29 44 47 50}, each of which
- 342 considered the trial to be 'good quality'²⁹, 'valid'⁴⁴, or 'high quality'⁵⁰. The trial was conducted in
- 343 1,231 hospital inpatients and found no evidence of a difference in PI incidence between patients
- 344 assessed with either the Waterlow scale or Ramstadius tool compared with clinical judgment alone
- 345 (RR 1.10, 95% CI 0.68, 1.81 for Waterlow and RR 0.79, 95% CI 0.46, 1.35 for Ramstadius). The trial
- 346 further showed no evidence of a difference in patient management or in PI severity when using a risk
- 347 assessment tool compared to clinical judgement.
- 348 The cluster randomised trial⁷¹ was considered to be of poor methodological quality in two reviews.²⁹
- ⁴⁷ The trial included 521 patients at a military hospital and compared nurse training with mandatory
- use of the Braden scale, to nurse training and optional use of the Braden scale, to no training. No
- evidence of a difference in PI incidence was observed between groups: incidence rates were 22%,
- 352 22% and 15% (p=0.38), for the three groups respectively.
- In both reviews by Lovegrove and colleagues,^{45 50} an uncontrolled comparison study⁷² was included.
 The study assessed the clinical effectiveness of the Maelor scale,⁷³ and was rated as high quality
 within the most recent review.⁵⁰ Preventive strategies and PI prevalence were compared across two
 sites, an Irish hospital that used the Maelor scale (121 patients) and a Norwegian hospital that used
- 357 nurses' clinical judgement (59 patients). A higher rate of preventive strategies, as well as a lower PI
- 358 prevalence (12% vs. 54%), was reported for the Irish hospital. However, these results are likely to be
- 359 highly confounded by inherent differences in population and setting.
- 360 A non-randomised study by Gunningberg and colleagues⁷⁴ was included in two reviews, one of which
- 361 is reported in Table 4^{33 69} and was considered to be of relatively high quality. The study was
- 362 conducted in 124 patients in emergency and orthopaedic units and compared the use of a pressure
- 363 ulcer risk alarm sticker for patients with a modified Norton Score of <21 (indicating high-risk patients)
- to standard care. No significant difference in the incidence of pressure ulcers between the Norton
- 365 scale and standard care groups was observed.
- 366 A non-randomised study⁷⁵ conducted in 233 hospice inpatients was included in three reviews,^{29 33 69}
- 367 one of which is reported in Table 4.⁶⁹ The study met six of eight quality criteria used by Health
- 368 Quality Ontario.⁶⁹ Use of a modified version of the Norton scale (Norton modified by Bale), in
- 369 conjunction with standardised use of preventive interventions based on risk score, was found to be
- associated with lower risk of pressure ulcers when compared with nurses' clinical judgment alone
- 371 (RR 0.11, 95% CI 0.03, 0.46). The lack of randomisation limits the reliability of this result, and review
- authors report that the modified Norton scale had not been validated.
- Finally, a 'before-and-after' study⁷⁶ of 181 patients in various hospital settings was included in two
 reviews. ^{33 69} The Health Quality Ontario considered the study to meet all quality criteria.⁶⁹ Use of the

Table 4. Systematic reviews evaluating clinical effectiveness

Review author (publication year)	Models included	Setting of included studies; study design; sample size	Included outcomes	Brief description of study quality	Relevant results from included studies
Lovegrove ⁵⁰ (2021)	Braden; Maelor score; Norton; Ramstadius; Waterlow	Acute care hospital n=1, inpatient units n=1, ICU n=1, internal medicine and oncology wards n=1; Design: cross-sectional survey n=2, RCT n=1, observational inter-rater reliability n=1; Sample size 45 to 1231	PI risk scores; PI incidence; PI preventative interventions; interrater reliability (reliability results covered in Appendix 5)	RoB assessed using JBI tools or analytical cross-sectional study appraisal checklist. The RCT was judged as high quality. Of the remaining studies, two were judged as high quality and one as moderate quality; inclusion criteria not clearly stated and no strategies to deal with confounding.	 There were no differences in patient management ('pressure care plan' and use of a special mattress) based on PI risk assessment method (clinical judgement, Ramstadius tool or Waterlow score). PI incidence difference between groups not significant (p = 0.44) (Webster 2011⁷⁰). A hospital that used the Maelor scale reported a higher rate of PI preventive strategies, and a lower PI prevalence (12% vs. 54%), than a site that used nurses' clinical judgement (Moore 2015⁷²).
Moore ⁴⁷ (2019)	Braden; Waterlow; Ramstadius	Military hospital n=1, internal medicine and oncology wards n=1; Design: RCT n=1, cluster randomised trial n=1; Sample sizes 286 and 1231	PI incidence; severity of PIs	RoB assessed using Cochrane tool (Higgins 2011 ⁴⁸). Both studies at high RoB due to blinding issues. One study at RoB also due to baseline imbalance and incorrect analyses.	 No differences in PI incidence when using Braden scale or clinical judgement (Braden vs. clinical judgement+training, RR 0.97, 95% CI 0.53-1.77; Braden vs clinical judgement RR 1.43, 95% CI 0.77-2.68) (Saleh 2009⁷¹). No difference in PI incidence when using a risk assessment tool compared to clinical judgement (RR 1.10, 95% CI 0.68-1.81 and RR 0.79, 95% CI 0.46-1.35, for Waterlow and Ramstadius respectively) (Webster 2011⁷⁰). No difference in PI severity based on risk assessment tools vs. clinical judgement (Webster 2011⁷⁰).
Chou ²⁹ (2013)	Norton modified by Bale; Braden; Waterlow; Ramstadius	Hospital n=2, hospice n=1; Design: non-randomised n=1, cluster randomised trial n=1, RCT n=1; Sample size 240 to 1231	PI incidence, severity of PIs; PI preventative interventions	RoB assessed with criteria consistent with AHRQ Methods Guide for Effectiveness and Comparative Effectiveness Reviews. One RCT was rated as good quality and the other as poor due to randomisation and blinding issues. The cohort study was rated as poor; there were blinding issues and confounding was not investigated.	 No difference in Pl incidence when using a risk assessment tool compared to clinical judgement (RR 1.10, 95% Cl 0.68-1.81 and RR 0.79, 95% Cl 0.46-1.35, for Waterlow and Ramstadius respectively) (Webster 2011⁷⁰). The modified version of the Norton scale with use of preventive interventions is associated with lower risk of Pls compared with clinical judgment (RR 0.11, 95% Cl 0.03-0.46) (Bale 1995⁷⁵). No difference in risk of Pls when one of three interventions was used (22% vs. 22% vs. 15%, p=0.38 for nurse training+mandatory Braden scale, nurse training+optional Braden scale and no training respectively) (Saleh 2009⁷¹).

Review author (publication year)	Models included	Setting of included studies; study design; sample size	Included outcomes	Brief description of study quality	Relevant results from included studies
Health Quality Ontario ⁶⁹ (2009)	Norton; Norton modified by Bale; Norton modified by Ek 97	Hip fracture inpatients n=1, palliative care/hospice n=1, neurosurgery, general medicine, orthopaedic, and oncology units n=1; Design: prospective controlled (contemporaneous controls) n=1, before-and-after n=1; Sample size 124 to 223	PI incidence; PI preventative interventions	RoB assessment criteria name not given. Two studies met 6/8 and one study met all quality assessment requirements. In the studies that didn't meet all requirements, there were blinding and loss to follow-up issues. One study used a version of the Norton scale that was not validated.	 Compared a strategy that gave high-risk patients (based on modified Norton score) a risk alarm sticker to standard care. No significant difference between the groups in the incidence of PIs (Gunningberg 1999⁷⁴). Compared a strategy where patients received a pressure support system allocated according to the modified Norton scale to one where the nurse chose whether to give a special mattress. Using the scale significantly reduced the incidence of PIs (22.4% vs. 2.5%, p<0.0001) (Bale 1995⁷⁵). Compared the Norton scale with training to standard care. There was a significant difference in the number of preventative interventions (18.96 vs. 10.75, for Norton and usual care respectively). Interventions were used earlier for Norton vs. usual care (on day 1, 61% vs. 50%, p<0.002). No significant difference in the incidence of PIs (290⁷⁶).

376 AHRQ – Agency for Healthcare Research; CASP – Critical Appraisal Skills Checklist; CI – confidence interval; ICU – intensive care unit; JBI – Joanna Briggs Institute; PI – pressure injury; RCT –

377 randomised controlled trial; RoB – risk of bias; RR – Risk Ratio; S.S. – Suriadi Sanada Scale.

- 378 Norton scale with additional training for staff was associated with significant differences in the
- number of preventative interventions prescribed compared to standard care (18.96 vs. 10.75,
- 380 respectively). Preventative interventions were also introduced earlier in the intervention group (on
- day 1, 61% vs. 50%, P<0.002 for Norton and usual care, respectively). However, no significant
- difference in the incidence of PIs was detected between the groups.

383 DISCUSSION

- This umbrella review summarises data from a total of 23 systematic reviews of studies evaluating the clinical utility of a total of 63 PI risk prediction tools. Despite the large number of available reviews, quality assessment using an adaptation of AMSTAR-2 suggested that the majority were conducted to a relatively poor standard or did not meet reporting standards for systematic reviews.^{14 26} Of the 15 items included in AMSTAR-2, only two (for accuracy reviews) and four (for effectiveness reviews)
- criteria were more consistently met (more than 60% of reviews scoring 'Yes'). All other criteria were
 fully met by less than half of reviews. The primary studies included in the reviews were particularly
- 391 poorly described in the accuracy reviews, making it difficult to determine exactly what was evaluated
- and in whom. In particular, the source of the data was poorly reported. Only one review³³ explicitly
- restricted to accuracy estimates from external validations, and only one review²⁹ described whether
- 394 estimates were sourced from training or external data. The extent to which we could reliably
- describe and comment on the content of the reviews is limited and high-quality evidence for the
- accuracy and clinical effectiveness of PI risk prediction models may be lacking.

397 Prognostic accuracy of risk prediction models

- 398 Of the 16 reviews focused on the predictive accuracy of included models, only two used appropriate
- 399 methods for both quality assessment and statistical synthesis of accuracy data^{36 40}, one of which³⁶
- 400 evaluated only the Braden scale. Only one review³³ pre-specified the exclusion of studies reporting
- tool development only, one review restricted to "validated risk assessment instruments" only²⁹, and
- 402 none of the reviews discussed the importance of appropriate validation of prediction models. Only
- two reviews conducted meta-analyses at different cut-offs for determination of high risk^{29 36}; the
 remaining reviews combined data regardless of the threshold used. Combining data across different
- 405 thresholds to estimate summary sensitivity and specificity is discouraged as it yields clinically
- 406 uninterpretable and non-generalisable estimates, because the estimates do not relate to a particular
- 407 threshold.²⁵
- 408 Results of meta-analyses suggested that risk prediction scales have moderate sensitivities and
- 409 somewhat lower specificities, typically in the range of around 70% to 85% for sensitivity and as low
- 410 as 30% to 40% for specificity for some tools. Without a detailed review of the primary study
- 411 publications for these models, it is not possible to assess which, if any, of these risk assessment
- 412 scales might outperform the others. It seems that limited comparative studies comparing the
- 413 accuracy of different tools are available.
- For the ML-based models, one review³⁰ meta-analysed accuracy data by algorithm type. The results 414 415 of the meta-analyses are not informative for clinical practice but may be a useful way of identifying 416 which ML algorithms may be more suited to the data. Results suggested that specificities for random 417 forest or decision tree models could reach 90% or above with associated sensitivities in the range of 418 66% to 72%, however relatively wide confidence intervals around these summary estimates reflect 419 considerable variation in model performance. Moreover, some of these estimates came from internal 420 validations within model development studies, and may not be transferable to other settings.⁷⁷ 421 Authors should make it clear where accuracy estimates are derived from to avoid overinterpretation 422 of results.

423 Clinical effectiveness of risk prediction scales

- 424 Prediction models, like any test used for diagnostic or prognostic purposes, require evaluation in the
- 425 care pathway to identify the extent to which their use can impact on health outcomes.⁷⁸ Of the 10
- 426 reviews assessing clinical effectiveness of PI risk prediction tools, the only primary studies suggesting
- 427 potential patient benefits from the use of risk prediction tools,^{72 75 76} were non-randomised and are
- 428 likely to be at high risk of bias. In contrast, two randomised trials,^{70 71} (both considered at high risk of
- 429 bias by the Cochrane review⁴⁷) suggest that use of structured risk assessment tools does not reduce
- the incidence of PIs. We should recognise that effectiveness outcomes largely depend on the
- 431 availability and efficacy of preventative measures, and conclusions regarding the clinical effectiveness
- 432 of these risk assessment tools cannot be confidently drawn from the limited evidence available. All
- reviews included studies that assessed the use of risk assessment scales developed by experts, and
- no evidence is available evaluating the clinical effectiveness of empirically derived prediction models
- 435 or ML algorithms.

436 Other existing evidence

437 Moore and colleagues⁴⁷ recently updated their review (published after our search was conducted⁷⁹)

- and reported no new randomised trials that assessed the effect of risk assessment tools on PIincidence.
- 440 We have separately reviewed⁹ available evidence for the development and validation of risk
- 441 prediction tools for PI occurrence. Almost half (52/116, 45%) of available tools were developed using
- 442 ML methods (as defined by review authors), 40% (46/116) were based on clinical expertise or
- 443 unclear methods, and only 18 (16%) were identified as having used statistical modelling methods.
- 444 The reviews varied in methodological quality and reporting; however, the reporting of prediction
- 445 model development in the original primary studies appears to be poor. For example, across all
- 446 prediction tools identified, the internal validation approach was unclear and unidentifiable for 70%
- 447 (81/116) of tools, and only one review identified and included external validation studies (n=7
- 448 studies).
- 449 ML-based models may have potential for identifying those at risk of PI, as suggested by one review³⁰
- 450 included in this umbrella review. However, it is important to consider the lack of transparency in
- 451 reporting of model development methods and model performance, and the concerning lack of
- 452 model validation in populations outside of the original model development sample.⁹

453 Strengths and limitations

- 454 We have conducted the first umbrella review that summarise the prognostic accuracy and clinical
- 455 effectiveness of prediction models for risk of PI. We followed Cochrane guidance¹³, with a highly
- 456 sensitive search strategy designed by an experienced information specialist. Although we excluded
- 457 non-English publications due to time and resource constraints, where possible these publications
- 458 were used to identify additional eligible risk prediction models. To some extent, our review is limited
- by the use of AMSTAR-2 for quality assessment of included reviews. AMSTAR-2 was not designed for
- 460 assessing systematic reviews of diagnostic or prognostic studies. Although we made some
- adaptations, many of the existing and amended criteria relate to the quality of reporting of the
- reviews as opposed to methodological quality. There is scope for further work to establish criteria for
- 463 assessing systematic reviews of prediction models.
- The primary limitation of our study lies in the limited detail available on risk prediction tools and
- their performance within the included systematic reviews. To ensure comprehensive model
- 466 identification, we adopted a broad definition of 'systematic,' potentially influencing the depth of
- 467 information provided in the reviews, and the reporting quality in many primary studies contributing

- to these reviews may be suboptimal. Notably, excluding ML-based models, over half of the existing
 risk prediction tools were published prior to 2000, before the publication of original versions of
- 470 reporting guidelines for diagnostic accuracy studies⁸⁰ and risk prediction models.⁸¹

471 CONCLUSIONS

- 472 In conclusion, this umbrella review comprehensively summarises the prognostic accuracy and clinical
- 473 effectiveness of risk prediction tools for developing PIs. The included systematic reviews used poor
- 474 methodology and reporting, limiting our ability to reliably describe and evaluate their content. ML-
- based models demonstrated potential, with high specificity reported for some models. Wide
- 476 confidence intervals highlight the variability in current evaluations, and external validation of ML
- 477 tools may be lacking. The prognostic accuracy of clinical scales and statistically derived prediction
- 478 models has a substantial range of specificities and sensitivities, motivating further model
- 479 development with high quality data and appropriate statistical methods.
- 480 Regarding clinical effectiveness, a reduction of PI incidence is unclear due the overall uncertainty and
- 481 potential biases in available studies. This underscores the need for further research in this critical
- 482 area, once promising prediction tools have been developed and appropriately validated. In particular,
- the clinical impact of newer ML-based models currently remains largely unexplored. Despite these
- 484 limitations, our umbrella review provides valuable insights into the current state of PI risk prediction
- 485 tools, emphasising the need for robust research methods to be used in future evaluations.

486

487 Acknowledgements

488 We would like to thank Mrs. Rosie Boodell (University of Birmingham, UK) for her help in acquiring 489 the publications necessary to complete this piece of work.

490 Author Contributions

- 491 **Conceptualisation:** Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout
- 492 Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes
- 493 Data curation: Bethany Hillier, Katie Scandrett, April Coombe, Jacqueline Dinnes
- 494 Formal analysis: Bethany Hillier, Katie Scandrett, Jacqueline Dinnes
- 495 Funding acquisition: Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes
- 496 Investigation: Bethany Hillier, Katie Scandrett, April Coombe, Yemisi Takwoingi, Jacqueline Dinnes
- 497 Methodology: Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout
- 498 Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes
- 499 Project administration: Bethany Hillier, Yemisi Takwoingi, Jacqueline Dinnes
- 500 Resources: Bethany Hillier, Katie Scandrett
- 501 Supervision: Yemisi Takwoingi, Jacqueline Dinnes
- 502 Writing original draft: Bethany Hillier, Katie Scandrett, April Coombe, Jacqueline Dinnes
- 503 Writing review & editing: Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard,
- 504 Ewout Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

505 Funding

- 506 This work was commissioned and supported by Paul Hartmann AG (Heidenheim, Germany). The
- 507 contract with the University of Birmingham was agreed on the legal understanding that the authors
- 508 had the freedom to publish results regardless of the findings.
- 509 YT, JD, BH, KS and AC are funded by the National Institute for Health and Care Research (NIHR)
- 510 Birmingham Biomedical Research Centre (BRC). This paper presents independent research supported
- 511 by the NIHR Birmingham BRC at the University Hospitals Birmingham NHS Foundation Trust and the
- 512 University of Birmingham. The views expressed are those of the authors and not necessarily those of
- 513 the NIHR or the Department of Health and Social Care.

514 Conflicting Interests

- 515 I have read the journal's policy and the authors of this manuscript have the following competing
- 516 interests: VV is an employee of Paul Hartmann AG; ES and THB received consultancy fees from Paul
- 517 Hartmann AG. All other authors received no personal funding or personal compensation from Paul
- 518 Hartmann AG and have declared that no competing interests exist.
- 519

520 References

531

- Li Z, Lin F, Thalib L, et al. Global prevalence and incidence of pressure injuries in hospitalised adult
 patients: A systematic review and meta-analysis. *International Journal of Nursing Studies* 2020;105:103-546. doi: 10.1016/j.ijnurstu.2020.103546
- 2. Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United
 States. *Int Wound J* 2019;16(3):634-40. doi: 10.1111/iwj.13071 [published Online First:
 2019/01/28]
- Sullivan N, Schoelles K. Preventing In-Facility Pressure Ulcers as a Patient Safety Strategy. *Annals of Internal Medicine* 2013;158(5.2):410-16. doi: 10.7326/0003-4819-158-5-201303051-00008
- 4. Institute for Quality and Efficiency in Health Care (IQWiG). Preventing pressure ulcers. Cologne,
 Germany 2006 [updated 2018 Nov 15. Available from:
 - https://www.ncbi.nlm.nih.gov/books/NBK326430/?report=classic accessed Feb 2023].
- 5. Braden B, Bergstrom N. A Conceptual Schema for the Study of the Etiology of Pressure Sores.
 Rehabilitation Nursing 1987;12(1):8-16. doi: 10.1002/j.2048-7940.1987.tb00541.x
- 6. Bergstrom N, Braden BJ, Laguzza A, et al. The Braden Scale for Predicting Pressure Sore Risk. *Nurs Res* 1987;36(4):205-10.
- 536 7. Norton D. Geriatric nursing problems. *Int Nurs Rev* 1962;9:39-41.
- 537 8. Waterlow J. Pressure sores: a risk assessment card. *Nursing Times* 1985;81:49-55.
- 9. Hillier B, Scandrett K, Coombe A, et al. Development and validation of risk prediction tools for
 pressure injury occurrence: An umbrella review (pre-print). *MedRxiv* 2024 doi: TBC (UPDATE
 ME)
- 541 10. Šimundić AM. Measures of Diagnostic Accuracy: Basic Definitions. *EJIFCC* 2009;19(4):203-11.
 542 [published Online First: 2009/01/20]
- Leeflang MM, Rutjes AW, Reitsma JB, et al. Variation of a test's sensitivity and specificity with
 disease prevalence. *CMAJ* 2013;185(11):E537-44. doi: 10.1503/cmaj.121286 [published
 Online First: 2013/06/24]
- 12. Maiga A, Farjah F, Blume J, et al. Risk Prediction in Clinical Practice: A Practical Guide for
 Cardiothoracic Surgeons. *Ann Thorac Surg* 2019;108(5):1573-82. doi:
 10.1016/j.athoracsur.2019.04.126 [published Online First: 2019/06/27]
- 13. Pollock M, Fernandes RM BL, Pieper D, Hartling L, Chapter V: Overviews of Reviews. In: Higgins
 JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA ed. Cochrane Handbook for
 Systematic Reviews of Interventions version 63 (updated February 2022). Available from
 www.training.cochrane.org/handbook: Cochrane 2022.
- 14. McInnes MDF, Moher D, Thombs BD, et al. Preferred Reporting Items for a Systematic Review and
 Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA
 2018;319(4):388-96. doi: 10.1001/jama.2017.19163
- 55615. Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. J Am Med Inform Assoc5572001;8(4):391-7. doi: 10.1136/jamia.2001.0080391 [published Online First: 2001/06/22]
- 16. Wilczynski NL, Haynes RB. Optimal Search Strategies for Detecting Clinically Sound Prognostic
 Studies in EMBASE: An Analytic Survey. *Journal of the American Medical Informatics Association* 2005;12(4):481-85. doi: 10.1197/jamia.M1752
- 17. Geersing G-J, Bouwmeester W, Zuithoff P, et al. Search Filters for Finding Prognostic and
 Diagnostic Prediction Studies in Medline to Enhance Systematic Reviews. *PLOS ONE* 2012;7(2):e32844. doi: 10.1371/journal.pone.0032844
- 18. NHS. Pressure ulcers: revised definition and measurement. Summary and recommendations 2018
 [Available from: <u>https://www.england.nhs.uk/wp-content/uploads/2021/09/NSTPP-</u>
 <u>summary-recommendations.pdf</u> accessed Feb 2023].
- 19. Haesler E. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and
 Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries:
 Clinical Practice Guideline. 2019 [Available from: https://internationalguideline.com/2019
 accessed Feb 2023].

- 571 20. AHCPR. Pressure ulcer treatment. : Agency for Health Care Policy and Research 1994:1-25.
- 572 21. Harker J. Pressure ulcer classification: the Torrance system. *Journal of Wound Care* 2000;9(6):275573 77. doi: 10.12968/jowc.2000.9.6.26233
- 574 22. Moons KGM, de Groot JAH, Bouwmeester W, et al. Critical Appraisal and Data Extraction for
 575 Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. *PLOS Medicine* 576 2014;11(10):e1001744. doi: 10.1371/journal.pmed.1001744
- 577 23. Cochrane. DE form example prognostic models scoping review: The Cochrane Collaboration: The
 578 Prognosis Methods Group; [Available from: <u>https://methods.cochrane.org/prognosis/tools</u>
 579 accessed Feb 2023].
- Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that
 include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008. doi: 10.1136/bmj.j4008
- 25. P M, Y T, JJ D, et al. Understanding meta-analysis. Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi
 Y (editors) Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version
 2.0 ed: Cochrane, 2023 (updated July 2023).
- 26. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097. doi:
 10.1371/journal.pmed.1000097
- 589 27. Munoz N, Posthauer ME. Nutrition strategies for pressure injury management: Implementing the
 2019 International Clinical Practice Guideline. *Nutrition in Clinical Practice* 2022;37(3):567 591 82.
- 28. Park SH, Lee YS, Kwon YM. Predictive Validity of Pressure Ulcer Risk Assessment Tools for Elderly:
 A Meta-Analysis. Western journal of nursing research 2016;38:459-83. doi:
 10.1177/0193945915602259
- 59529. Chou R, Dana T, Bougatsos C, et al. Pressure ulcer risk assessment and prevention: a systematic596comparative effectiveness review. Annals of internal medicine 2013;159(1):28-38.
- 30. Qu C, Luo W, Zeng Z, et al. The predictive effect of different machine learning algorithms for
 pressure injuries in hospitalized patients: A network meta-analyses. *Heliyon* 2022;8(11):e11361. doi: 10.1016/j.heliyon.2022.e11361
- 31. Wang N, Lv L, Yan F, et al. Biomarkers for the early detection of pressure injury: A systematic
 review and meta-analysis. *Journal of Tissue Viability* 2022;31:259-67. doi:
 10.1016/j.jtv.2022.02.005
- 32. García-Fernández FP, Pancorbo-Hidalgo PL, Agreda JJS. Predictive Capacity of Risk Assessment
 Scales and Clinical Judgment for Pressure Ulcers: A Meta-analysis. *Journal of Wound Ostomy & Continence Nursing* 2014;41(1):24-34. doi: 10.1097/01.WON.0000438014.90734.a2
- 33. Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Lopez-Medina IM, et al. Risk assessment scales for
 pressure ulcer prevention: a systematic review. *J Adv Nurs* 2006;54(1):94-110. doi:
 10.1111/j.1365-2648.2006.03794.x
- 34. Chen HL, Shen WQ, Liu P. A Meta-analysis to Evaluate the Predictive Validity of the Braden Scale
 for Pressure Ulcer Risk Assessment in Long-term Care. Ostomy/wound management
 2016;62(9):20-8.
- 35. He W, Liu P, Chen HL. The Braden Scale cannot be used alone for assessing pressure ulcer risk in
 surgical patients: a meta-analysis. *Ostomy/wound management* 2012;58:34-40.
- 36. Huang C, Ma Y, Wang C, et al. Predictive validity of the braden scale for pressure injury risk
 assessment in adults: A systematic review and meta-analysis. *Nursing open* 2021;8:2194-207.
 doi: 10.1002/nop2.792

617 37. Park SH, Choi YK, Kang CB. Predictive validity of the Braden Scale for pressure ulcer risk in 618 hospitalized patients. *Journal of Tissue Viability* 2015;24:102-13. doi: 619 10.1016/j.jtv.2015.05.001

620 38. Wei M, Wu L, Chen Y, et al. Predictive Validity of the Braden Scale for Pressure Ulcer Risk in Critical Care: A Meta-Analysis. Nursing in critical care 2020;25:165-70. doi: 621 622 10.1111/nicc.12500 623 39. Wilchesky M, Lungu O. Predictive and concurrent validity of the Braden scale in long-term care: A 624 meta-analysis. Wound Repair and Regeneration 2015;23:44-56. doi: 10.1111/wrr.12261 625 40. Zhang Y, Zhuang Y, Shen J, et al. Value of pressure injury assessment scales for patients in the intensive care unit: Systematic review and diagnostic test accuracy meta-analysis. Intensive & 626 627 critical care nursing 2021;64:103009. doi: 10.1016/j.iccn.2020.103009 628 41. Kottner J, Dassen T, Tannen A. Inter- and intrarater reliability of the Waterlow pressure sore risk 629 scale: A systematic review. International Journal of Nursing Studies 2009;46:369-79. doi: 630 10.1016/j.ijnurstu.2008.09.010 631 42. Tayyib NAH, Coyer F, Lewis P. Pressure ulcers in the adult intensive care unit: a literature review of 632 patient risk factors and risk assessment scales. Journal of Nursing Education and Practice 633 2013;3(11):28-42. 634 43. Baris N, Karabacak BG, Alpar SE. The Use of the Braden Scale in Assessing Pressure Ulcers in 635 Turkey: A Systematic Review. Advances in skin & wound care 2015;28:349-57. doi: 10.1097/01.ASW.0000465299.99194.e6 636 637 44. Gaspar S, Peralta M, Margues A, et al. Effectiveness on hospital-acquired pressure ulcers 638 prevention: a systematic review. International Wound Journal 2019;16(5):1087-102. doi: 639 10.1111/iwj.13147 640 45. Lovegrove J, Miles S, Fulbrook P. The relationship between pressure ulcer risk assessment and 641 preventative interventions: a systematic review. Journal of wound care 2018;27(12):862-75. 642 46. Kelly J. Inter-rater reliability and Waterlow's pressure ulcer risk assessment tool. Nurs Stand 2005;19(32):86-7, 90-2. doi: 10.7748/ns2005.04.19.32.86.c3851 643 644 47. Moore ZEH, Patton D. Risk assessment tools for the prevention of pressure ulcers. Cochrane 645 Database of Systematic Reviews 2019 doi: 10.1002/14651858.CD006471.pub4 646 48. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of 647 bias in randomised trials. BMJ 2011;343:d5928. doi: 10.1136/bmj.d5928 648 49. AHRQ Methods for Effective Health Care. Methods Guide for Effectiveness and Comparative 649 Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US) 650 2008. 651 50. Lovegrove J, Ven S, Miles SJ, et al. Comparison of pressure injury risk assessment outcomes using a structured assessment tool versus clinical judgement: A systematic review. Journal of 652 653 Clinical Nursing 2021 doi: 10.1111/jocn.16154 [published Online First: 2021/12/01] 654 51. Song M, Choi KS. Factors predicting development of decubitus ulcers among patients admitted for neurological problems. The Journal of Nurses Academic Society 1991;21(1):16-26. 655 656 52. Pang SM, Wong TK. Predicting pressure sore risk with the Norton, Braden, and Waterlow scales in 657 a Hong Kong rehabilitation hospital. Nursing Research 1998;47(3):147-53. 658 53. Park SH, Lee HS. Assessing Predictive Validity of Pressure Ulcer Risk Scales- A Systematic Review 659 and Meta-Analysis. Iranian journal of public health 2016;45(2):122-33. 660 54. Cubbin B, Jackson C. Trial of a pressure area risk calculator for intensive therapy patients. 661 Intensive Care Nursing 1991;7(1):40-44. 55. González-Ruiz J, Carrero AG, Blázquez MH, et al. Factores de riesgo de las úlceras por presión en 662 663 pacientes críticos. Enfermería Clinica 2001;11(5):184-90. 56. Macaskill P, Gatsonis C, Deeks J, et al. Cochrane handbook for systematic reviews of diagnostic 664 665 test accuracy: Version, 2010. 666 57. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002;21(9):1237-56. doi: 10.1002/sim.1099 667 58. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a 668 669 summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 670 1993;12(14):1293-316. doi: 10.1002/sim.4780121403

671 59. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making 1993;13(4):313-21. doi: 672 10.1177/0272989x9301300408 673 674 60. Kwong E, Pang S, Wong T, et al. Predicting pressure ulcer risk with the modified Braden, Braden, 675 and Norton scales in acute care hospitals in Mainland China. Appl Nurs Res 2005;18(2):122-8. 676 doi: 10.1016/j.apnr.2005.01.001 677 61. Halfens R, Van Achterberg T, Bal R. Validity and reliability of the Braden scale and the influence of 678 other risk factors: a multi-centre prospective study. International Journal of Nursing Studies 679 2000;37(4):313-19. 680 62. Ek AC. Prediction of pressure sore development. Scand J Caring Sci 1987;1(2):77-84. doi: 681 10.1111/j.1471-6712.1987.tb00603.x 682 63. Bienstein C. Risikopatienten erkennen mit der erweiterten Nortonskala [Risk patients detected 683 with the extended Norton scale]. Dekubitus - Prophylaxe undTherapie. Frankfurt/Main: 684 Verlag Krankenpflege 1991. 685 64. Jackson C. The revised Jackson/Cubbin Pressure Area Risk Calculator. Intensive Crit Care Nurs 1999;15(3):169-75. doi: 10.1016/s0964-3397(99)80048-2 686 687 65. Fuentelsaz C. Validation of the EMINA scale: tool for the evaluation of risk of developing pressure 688 ulcers in hospitalized patients. Enferm Clin [Internet] 2001;11(3):97-103. 689 66. Lowthian P. The practical assessment of pressure sore risk. Care-Science and Practice 690 1987;5(4):3-7. 691 67. Lowery MT. A pressure sore risk calculator for intensive care patients: 'the Sunderland 692 experience'. Intensive Crit Care Nurs 1995;11(6):344-53. doi: 10.1016/s0964-3397(95)80452-693 8 68. Lindgren M, Unosson M, Krantz AM, et al. A risk assessment scale for the prediction of pressure 694 695 sore development: reliability and validity. Journal of advanced nursing 2002;38(2):190-99. 696 69. Ontario HQ. Pressure ulcer prevention: an evidence-based analysis. Ontario health technology 697 assessment series 2009;9(2):1-104. 698 70. Webster J, Coleman K, Mudge A, et al. Pressure ulcers: effectiveness of risk-assessment tools. A randomised controlled trial (the ULCER trial). BMJ Quality & amp; amp; Safety 699 700 2011;20(4):297. doi: 10.1136/bmjqs.2010.043109 701 71. Saleh M, Anthony D, Parboteeah S. The impact of pressure ulcer risk assessment on patient 702 outcomes among hospitalised patients. J Clin Nurs 2009;18(13):1923-9. doi: 10.1111/j.1365-703 2702.2008.02717.x [published Online First: 2009/04/03] 704 72. Moore Z, Johansen E, Etten Mv, et al. Pressure ulcer prevalence and prevention practices: a cross-705 sectional comparative survey in Norway and Ireland. Journal of Wound Care 2015;24(8):333-706 39. doi: 10.12968/jowc.2015.24.8.333 707 73. Moore Z, Pitman S. Towards establishing a pressure sore prevention and management policy in 708 an acute hospital setting. The All Ireland Journal of Nursing and Midwifery 2000;1(1):7-11. 709 74. Gunningberg L, Lindholm C, Carlsson M, et al. Implementation of risk assessment and 710 classification of pressure ulcers as quality indicators for patients with hip fractures. J Clin 711 Nurs 1999;8(4):396-406. doi: 10.1046/j.1365-2702.1999.00287.x 712 75. Bale S, Finlay I, Harding KG. Pressure sore prevention in a hospice. J Wound Care 1995;4(10):465-713 8. doi: 10.12968/jowc.1995.4.10.465 714 76. Hodge J, Mounter J, Gardner G, et al. Clinical trial of the Norton Scale in acute care settings. Aust 715 J Adv Nurs 1990;8(1):39-46. 716 77. Steyerberg EW, Harrell FE, Jr. Prediction models need appropriate internal, internal-external, and 717 external validation. J Clin Epidemiol 2016;69:245-7. doi: 10.1016/j.jclinepi.2015.04.005 718 [published Online First: 2015/04/18] 719 78. Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models: II. External validation, model 720 updating, and impact assessment. Heart 2012;98(9):691-8. doi: 10.1136/heartjnl-2011-721 301247 [published Online First: 2012/03/07]

- 722 79. Moore Z, Avsar P, O'Connor T, et al. A systematic review of movement monitoring devices to aid
 723 the prediction of pressure ulcers in at-risk adults. *International Wound Journal* 724 2023;20(2):579-608. doi: 10.1111/iwj.13902
- 80. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic
 accuracy: explanation and elaboration. *Ann Intern Med* 2003;138(1):W1-12. doi:
 10.7326/0003-4819-138-1-200301070-00012-w1
- 81. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction
 model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann*
- 730 *Intern Med* 2015;162(1):W1-73. doi: 10.7326/m14-0698